ALS drug shows promise in slowing disease
NCT ID NCT00424463
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tested a drug called MCI-186 (edaravone) in 181 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease and keep patients functioning longer. Participants received either the drug or a placebo, and researchers measured changes in daily abilities and safety over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Hospital Organization Miyagi National Hospital
Watari-gun, Miyagi, Japan
Conditions
Explore the condition pages connected to this study.